Nantahala Discloses 2.62M Shares (5.09%) in ABEO Schedule 13G
Rhea-AI Filing Summary
A Nantahala Capital Partners Schedule 13G filed for ABEONA THERAPEUTICS INC. reports shared beneficial ownership of 5.09% of common stock as of 09/29/2025. Nantahala discloses beneficial ownership of 2,618,462 shares, which includes 179,832 shares exercisable within sixty days. The filing states Nantahala holds no sole voting or dispositive power and reports shared voting and dispositive power for the full amount. The ownership percentage is calculated using a reported outstanding share count of 51,278,539 shares from the issuer's Form 10-Q for the period ended 06/30/2025. Signatures by compliance and management representatives are dated 10/06/2025.
Positive
- Clear disclosure of beneficial ownership totaling 2,618,462 shares
- Includes exercisable securities (179,832 shares) within sixty days for transparency
- Filed as Schedule 13G, indicating a passive intent rather than an active acquisition
Negative
- Crosses the 5% threshold (5.09%), which can attract market scrutiny
- Shared voting/dispositive power means exact influence is not isolated to a single holder
Insights
Nantahala reports a 5.09% stake held with shared voting power, triggering Schedule 13G disclosure.
The filing shows 2,618,462 shares beneficially owned, including 179,832 exercisable shares within sixty days; all voting and dispositive power is reported as shared, not sole. That classification signals passive investor status under the rules rather than an intent to influence control.
Key near-term items to watch are any amendments that shift to Schedule 13D or changes in voting/dispositive power, which would indicate an active intent to influence corporate control within weeks to months.
The stake represents a measurable but non-controlling position equal to about one twentieth of outstanding shares.
A 5.09% holding can attract attention from the market and other holders because it crosses the 5% reporting threshold; however, the filing explicitly certifies no intent to change or influence control. The inclusion of exercisable securities (179,832 shares) modestly increases the reported position.
Investors should note the reported outstanding share base of 51,278,539 from the issuer's Form 10-Q; any share count updates could change the percentage materially in the next quarterly disclosure cycle.
FAQ
What stake does Nantahala Capital hold in Abeona Therapeutics (ABEO)?
Does the Schedule 13G filing indicate Nantahala seeks control of ABEO?
Are any of the reported shares exercisable or subject to conversion?
How was the ownership percentage calculated?
Who signed the Schedule 13G for Nantahala?